1.
Real-world outcomes, treatment patterns and T790M testing rates in Non-Small Cell Lung Cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT: Outcomes and treatments of EGFR-mutated NSCLC patients from Slovenia. Radiol Oncol. 2022;56(3):371-379. Accessed November 21, 2026. https://www.radioloncol.com/index.php/ro/article/view/3840